RT Journal Article
T1 Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.
A1 Akkerman, Onno
A1 Aleksa, Alena
A1 Alffenaar, Jan-Willem
A1 Al-Marzouqi, Nada Hassan
A1 Arias-Guillén, Miguel
A1 Belilovski, Evgeny
A1 Bernal, Enrique
A1 Boeree, Martin J
A1 Borisov, Sergey E
A1 Bruchfeld, Judith
A1 Cadiñanos Loidi, Julen
A1 Cai, Qingshan
A1 Caminero, Jose A
A1 Cebrian Gallardo, Jose Joaquín
A1 Centis, Rosella
A1 Codecasa, Luigi Ruffo
A1 D'Ambrosio, Lia
A1 Dalcolmo, Margareth
A1 Danila, Edvardas
A1 Dara, Masoud
A1 Davidavičienė, Edita
A1 Davies Forsman, Lina
A1 De Los Rios Jefe, Jorge
A1 Denholm, Justin
A1 Duarte, Raquel
A1 Elamin, Seifeldin Eltaeb
A1 Ferrarese, Maurizio
A1 Filippov, Alexey
A1 Ganatra, Shashank
A1 Garcia, Ana
A1 García-García, José-María
A1 Gayoso, Regina
A1 Giraldo Montoya, Angela Maria
A1 Gomez Rosso, Roscio Gomez
A1 Gualano, Gina
A1 Hoefsloot, Wouter
A1 Ilievska-Poposka, Biljana
A1 Jonsson, Jerker
A1 Khimova, Elena
A1 Kuksa, Liga
A1 Kunst, Heinke
A1 Laniado-Laborín, Rafael
A1 Li, Yang
A1 Magis-Escurra, Cecile
A1 Manfrin, Vinicio
A1 Manga, Selene
A1 Marchese, Valentina
A1 Martínez Robles, Elena
A1 Maryandyshev, Andrei
A1 Matteelli, Alberto
A1 Migliori, Giovanni Battista
A1 Mullerpattan, Jai B
A1 Munoz-Torrico, Marcela
A1 Mustafa Hamdan, Hamdan
A1 Nieto Marcos, Magnolia
A1 Noordin, Noorliza Mohamad
A1 Palmero, Domingo Juan
A1 Palmieri, Fabrizio
A1 Payen, Marie-Christine
A1 Piubello, Alberto
A1 Pontali, Emanuele
A1 Pontarelli, Agostina
A1 Quirós, Sarai
A1 Rendon, Adrian
A1 Skrahina, Alena
A1 Šmite, Agnese
A1 Solovic, Ivan
A1 Sotgiu, Giovanni
A1 Souleymane, Mahamadou Bassirou
A1 Spanevello, Antonio
A1 Stošić, Maja
A1 Tadolini, Marina
A1 Tiberi, Simon
A1 Udwadia, Zarir Farokh
A1 van den Boom, Martin
A1 Vescovo, Marisa
A1 Viggiani, Pietro
A1 Visca, Dina
A1 Zhurkin, Dmitry
A1 Zignol, Matteo
A1 members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring, 
K1 Adverse events
K1 Bedaquiline
K1 Delamanid
K1 MDR-TB
K1 Monitoring
K1 Tuberculosis
AB The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019.
YR 2019
FD 2019-04-03
LK https://hdl.handle.net/10668/26651
UL https://hdl.handle.net/10668/26651
LA en
DS RISalud
RD Apr 14, 2025